Agree that we are hiding in plain view from mainstream which makes investing in this company a rare opportunity. Low cost and much higher reward - this is where you want to be in the CNS game. Get some and hold...
As for the 2 spin offs you mention, Denali, and Alector, (both backing genetic approaches), they appear, in my opinion, to be developing hypotheses as opposed to allowing the data to appear and following it to a solution as is the Missling/Anavex approach (as I see it).
Also, Denali and Alector are lagging Anavex in trials currently but both are already partnered up. Possibility to pick up speed, but limited profits already cooked in and once you hook up with a BP chance for “too many chefs to spoil the approach and soup”.
Things are early and could come undone with multiple opinions weighing in, instead of letting the science steer.
I think your opening sentiment about Anavex not being discovered by mainstream is the takeaway and reason investors here are in optimal/prime position.
No fussy partners to contend with (sure it’s being run as a dictatorship right now, which reinforces the notion of one poster on the twitter feed - let’s put the rigor back in science! You can’t aim to water things down and make compromises to please everyone. The solution is not to gain a consensus - it’s to fix some cells which are not functioning properly.)
Great stuff, jimmy - thx!
Bio
News 
Market Data 
Discover 
